国产降纤酶治疗脑梗塞的前瞻性临床研究  

The Prospective Clinical Study on Defibrase Treating the Cerebral Infarction

作　　者：于增盛 孙顺昌[1] 王淑玲[1] 毕显梅[1] 胡新建[1] 陈宪琪[1] 彭忠芬 于敦波[1] 王清峰[1] 刘坤[1] 李武伦[1] 王玉洪[1] 韩仲岩[2] 

机构地区：[1]青岛市第八人民医院,266100 [2]青岛医学院附属医院

出　　处：《青岛医药卫生》2000年第3期165-166,共2页Qingdao Medical Journal

摘　　要：目的 为进一步研究国产降纤酶对脑梗塞的疗效。方法 采取随机双盲对照临床研究。在应用降纤酶治疗前及用药后第14天分别进行神经功能缺损评分(NDF),并进行日常生活能力评估(Barthel 氏指数)。同时检测血浆中纤维蛋白原含量、肝功和肾功。结果 降纤酶治疗组血浆纤维蛋白的原含量在用药后极显著降低(P<0.01)对肝功、肾功无影响。近期疗效降纤酶治疗组显著优于对照组。神经功能缺损评分及Barthel氏指数有显著进步(P<0.05)。结论 国产降纤酶有效地降低血浆纤维蛋白原含量是治疗急性脑梗塞有较好疗效的药物。Objective To assess the effects of domestic defibrase on the treatment outcome of patients with cerebral infarction. Methods The clinical studies with double blind and comparative method. The nerve function deficit scores (NDF) were evaluated before treatment and in 14th day treated with defibrase and the routine life ability (Barthel index) . The serum fibrinogen concentration hepatic function and nephritic function were tested. Results The serum fibrinogen concentration in the trial group treated with defibrase decreased significantly (P<0. 01). The hepatic function and nephritic function were not affected. The effect of early period of the group treated with defibrase was improved much more than the control group. The nerve function deficit score and Barthel index of the group with difibrase improved much more than that of the control group. (P<0. 05). Conclusion The studies confirmed that the defibrase was a safe and effective drug to reduce the serum fibrinogen concentration and treat cerebral infarction.

关 键 词：降纤酶 脑梗塞 随机双盲 

分 类 号：R743.33[医药卫生—神经病学与精神病学]